Forvis acquired the U.S. unit of Mazars and formed a new network with the firm internationally, following plans by peers involving private equity, IPOs and a new employee ownership model.
More patients can fend off the disease for months or years with targeted or immune-boosting drugs, results released this weekend at a top cancer conference showed.
